Conclusion: A model using clinical and imaging data can accurately predict absence of high-risk varices in patients with HCC and avoid EGD in many patients prior to initiation of systemic therapy, thereby expediting care for patients with unresectable HCC
Bulking Agents (Microcystalline Cellulose, Dicalcium Phosphate), L-Glutathione, Anti-caking Agents (Silicon Dioxide, Magnesium Stearate), Biotin, Copper Sulphate.
In the landmark STEP 1 clinical trial, patients lost an average of 14.9% of body weight over 68 weeks compared to 2.4% with placebo
There are no head-to-head comparisons with popular drugs that have already been approved for weight-loss, but general numbers give some clues
The heavy carbs can also work against the appetite-regulating effects of GLP-1